Changes to the Small Business Innovative Research Program (SBIR) Competing Renewal Awards for Drug Development in Mental Health

Notice Number: NOT-MH-09-008

Key Dates
Release Date: March 13, 2009

Issued by
National Institute of Mental Health (NIMH) (

The purpose of this Notice is to inform the small business research community that NIMH is now accepting Phase II SBIR Competing Renewal Awards under the specific Funding Opportunity Announcement (FOA), PA-08-142, entitled “Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44]).”

Due to the increased difficulty for small businesses to receive outside funding for high risk drug development projects, NIMH will allow Phase II competing renewal awards, in response to this FOA, to include budgets up to $1.0 million total costs per year and time periods up to 3 years.  Total costs include direct costs, F&A, and fee/profit.   Applicants are encouraged to contact Dr. Margaret Grabb prior to submitting an SBIR application for this funding opportunity.

Additional information

For more information on this FOA, please see:

For more information on the NIH SBIR program, please see:


Inquiries regarding this Notice should be directed to:

Margaret Grabb, Ph.D.
National Institute of Mental Health
6001 Executive Boulevard, Room 7201, MSC 9645
Bethesda, MD 20892-9645
Rockville, MD 20852 (for express or courier service)
Telephone: (301) 443-3563

Weekly TOC for this Announcement
NIH Funding Opportunities and Notices

Office of Extramural Research (OER) - Home Page Office of Extramural
Research (OER)
  National Institutes of Health (NIH) - Home Page National Institutes of Health (NIH)
9000 Rockville Pike
Bethesda, Maryland 20892
  Department of Health and Human Services (HHS) - Home Page Department of Health
and Human Services (HHS) - Government Made Easy

Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.